Decompression vs. Fusion Surgery for Spinal Wear
Trial Summary
What is the purpose of this trial?
Adjacent segment disease (ASD) in the lumbar spine is a well-known sequela of lumbar fusion surgery. The annual incidence of adjacent level re-operation is approximately 3% with a ten-year prevalence of 20-30%. Frequently, the surgical treatment involves decompression of the adjacent level coupled with extension of the instrumentation and fusion. Advocates of this paradigm cite the altered kinematics and biomechanics of levels adjacent to a lumbar fusion mass. Furthermore, decompressed levels adjacent to a fused segments are associated with higher rates of ASD in retrospective studies. Yet, a retrospective review of higher quality data concluded decompression adjacent to single-level fusion provides similar outcomes compared to fusions extending across the decompressed segments. Given the conflicting data currently available, higher quality data are needed to guide surgical decision-making in ASD. The purpose of this trial is to prospectively compare decompression and decompression with fusion in patients with lumbar ASD.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Decompression vs. Fusion Surgery for Spinal Wear?
Research shows that both decompression and fusion surgeries can improve pain, function, and quality of life for patients with degenerative spinal conditions. However, studies have not found clear evidence that adding fusion to decompression provides additional benefits over decompression alone.12345
Is decompression or fusion surgery for spinal wear generally safe?
How is decompression surgery different from other treatments for spinal wear?
Decompression surgery, which involves relieving pressure on the spinal cord or nerves, is unique because it can be performed without fusion, leading to shorter hospital stays, less operative time, and lower surgical costs compared to when fusion is added. Studies have shown that decompression alone is as effective as decompression with fusion for certain spinal conditions, making it a simpler and potentially less risky option.1281011
Research Team
Daniel Tobert, MD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
This trial is for adults who've had lumbar fusion surgery involving L2 to the sacrum and are experiencing symptoms at the level above their fusion despite six weeks of non-surgical treatment. They should be at least one year post-op from a previous instrumented posterior lumbar fusion. Those with uninstrumented fusions, trauma, tumors, infections at the adjacent segment, prior pelvic fixations or instability won't qualify.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either decompression alone or decompression with extension of fusion for lumbar adjacent segment disease
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of post-operative narcotic utilization, pain intensity, anxiety, depression, and global health
Treatment Details
Interventions
- Decompression
- Extension Fusion
Decompression is already approved in European Union, United States, Canada for the following indications:
- Lumbar spinal stenosis
- Degenerative spondylolisthesis
- Adjacent segment disease
- Lumbar spinal stenosis
- Degenerative spondylolisthesis
- Adjacent segment disease
- Lumbar spinal stenosis
- Degenerative spondylolisthesis
- Adjacent segment disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor